Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

Pipeline
May. 2, 2022

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Read More
Apr. 28, 2022

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Read More
Apr. 26, 2022

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Read More